Half Year 2012 Results and R&D Highlights: DBV Technologies on Track

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: The Board of Directors of DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, chaired by Pierre-Henri Benhamou met on July 25, 2012 to review the financial statements for the first half 2012, published today. The full interim financial report (regulated information) is available on the Group's website, www.dbv-technologies.com, under the Regulated Information tab in the Investor Relations section. The 2012 half-year financial statements have been subject to a limited review by statutory auditors.